RxDoctor Payments Data

Sushan Joshi

Internal Medicine · Torrance, CANPI 1982851143

Payments from drug & device makers

$697in general payments, 2019–2025

Across 36 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$197
  • GSK$102
  • AbbVie$92
  • Novartis$59
  • Amgen$51
  • Agios Pharmaceuticals, Inc.$40
  • plus $156 from 9 others

What the payments were for

  • Food & beverage$697100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$697 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$124,987
Medicare patients
578
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$94,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$39,846
JardianceEmpagliflozin27$39,623
OzempicSemaglutide32$38,587
TrulicityDulaglutide29$32,183
JanuviaSitagliptin Phosphate18$22,996
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$18,469
EntrestoSacubitril/Valsartan13$18,254
XareltoRivaroxaban12$15,089
MounjaroTirzepatide13$14,842
MyrbetriqMirabegron18$12,533
Atorvastatin Calcium327$3,937
Metoprolol Succinate217$3,829
Albuterol Sulfate HfaAlbuterol Sulfate103$3,655
Irbesartan172$3,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$197$95,783107 claims
GSKTrelegy Ellipta, Anoro Ellipta$102$58,31471 claims
Boehringer IngelheimJardiance$13$39,62327 claims
Novo NordiskOzempic$30$38,58732 claims
MerckJanuvia$24$22,99618 claims
NovartisEntresto$59$18,25413 claims
Johnson & JohnsonXarelto$17$15,08912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →